BT-1053

N/A

Report date: 2023/05/05 17:34:32
NME

Base Information

Drug NameBT-1053
Drug Alias NameBT-1053
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTyrosine-protein kinase BTK inhibitors
TargetsTyrosine-protein kinase BTK
Therapy Area/IndicationsWaldenstrom MacroglobulinemiaLymphoma, Mantle-CellLymphoma, Follicular +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesScinnoHub Pharmaceutical Co LtdChengdu Brilliant Pharmaceutical Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesChengdu Brilliant Pharmaceutical Co LtdScinnoHub Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsWaldenstrom MacroglobulinemiaLymphoma, Mantle-CellLymphoma, Follicular +[6] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A